Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials DOI Creative Commons
Hazem Ayesh, Azizullah Beran,

Sajida Suhail

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2328 - 2328

Published: Oct. 14, 2024

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, metabolic syndrome, increasing liver-related morbidity cardiovascular risk. Recent therapies, including Resmetirom, FGF21 analogs, GLP-1 agonists, have shown promise. This network meta-analysis evaluates their comparative efficacy safety.

Language: Английский

Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials DOI Creative Commons
Hazem Ayesh, Azizullah Beran,

Sajida Suhail

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2328 - 2328

Published: Oct. 14, 2024

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, metabolic syndrome, increasing liver-related morbidity cardiovascular risk. Recent therapies, including Resmetirom, FGF21 analogs, GLP-1 agonists, have shown promise. This network meta-analysis evaluates their comparative efficacy safety.

Language: Английский

Citations

1